These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 19949333

  • 1. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
    Rosell R, Viteri S, Molina MA, Benlloch S, Taron M.
    Curr Opin Oncol; 2010 Mar; 22(2):112-20. PubMed ID: 19949333
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 8. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
    Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L.
    Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
    [Abstract] [Full Text] [Related]

  • 16. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS, Kobayashi S, Costa DB.
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [Abstract] [Full Text] [Related]

  • 17. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C.
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [Abstract] [Full Text] [Related]

  • 18. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL.
    Lung Cancer; 2017 Dec; 114():96-102. PubMed ID: 29173773
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.